Effects of Bempedoic Acid on CRP, IL-6, Fibrinogen and Lipoprotein(a) in Patients with Residual Inflammatory Risk:A Secondary Analysis of the CLEAR Harmony Trial

Bempedoic acid, an inhibitor of ATP citrate lyase, reduces low-density lipoprotein cholesterol (LDL-C)1, 2, 3, 4 and its impact on cardiovascular events is currently being evaluated among individuals at high vascular risk unable to achieve LDL goals with existing therapies.5 Similar to statins,6,7 bempedoic acid reduces high sensitivity C-reactive protein (hsCRP) by ∼20–30%, making it a potential therapeutic option for those with residual inflammatory or cholesterol risks.8

As with statins, the mechanisms underlying the potential anti-inflammatory effects of bempedoic acid are uncertain. Therefore, we sought to understand the impact of bempedoic acid on fibrinogen and interleukin-6, two important inflammatory markers, and the relationships between bempedoic acid–associated changes in biomarkers in patients from the randomized, placebo-controlled CLEAR Harmony trial. We focused our analysis on patients with residual inflammatory risk (with baseline hsCRP ≥2 mg/L). We also elected as part of the study design to assess the effects of bempedoic acid on lipoprotein(a).

留言 (0)

沒有登入
gif